Table 2 The FIGO stage-specific prevalence of HPV in early-stage CSCC patients
Stage | N | HPV (−), (%) | HPV (+), (%) (LR or HR) | HR-HPV (+), % | LR-HPV (+), % | ||
|---|---|---|---|---|---|---|---|
(FIGO 2009) | Single | Multiple | Subtotal | ||||
IA | 39 | 6 (15.4) | 33 (84.6) | 25 (64.1) | 7 (17.9) | 32 (82.0) | 4 (10.3) |
IB | 864 | 146 (16.9) | 718 (83.1) | 596 (69.0) | 108 (12.5) | 704 (81.5) | 44 (5.1) |
IIA | 522 | 72 (13.8) | 450 (86.2) | 377 (72.2) | 65 (12.5) | 442 (84.7) | 34 (6.5) |
Total cases | 1425 | 224 (15.7) | 1201 (84.3) | 998 (70.0) | 180 (12.6) | 1178 (82.6) | 82 (5.8) |